We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Abeona Therapeutics (ABEO) in Focus: Stock Up 5.7% in Session
Abeona Therapeutics Inc. was a big mover last session, as the company saw its shares rise around 6% on the day. Shares gained after the company announced encouraging data from its ongoing Phase I/II trial for ABO-102, a single treatment gene therapy strategy for patients with Sanfilippo syndrome type A. The news led to far more shares changing hands than in a normal session resulting in solid volume. This continues the recent uptrend for the company as the stock is now up 23.1% in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Abeona Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
ABEONA THERAPTC Price
ABEONA THERAPTC Price | ABEONA THERAPTC Quote
A better-ranked stock in the same industry is Agenus Inc. (AGEN - Free Report) , sporting a Zacks Rank #1 (Strong Buy).
Is ABEO going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>